Diquat PoisoningNCT05168111
The Correlation Between the Metabolism and the Functional Status of Multiple Organs in the Early Stage of Diquat Poisoning
An observational study of Diquat Poisoning, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Diquat Poisoning
- What is being tested?
- Detect the serum sample
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 2 Dec 2021to 30 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with acute poisoning of diquat are mainly selected.
Who may be able to join
- 1.Time from poisoning to hospital admission: within 6 hours, 2 The age is greater than 18 years old, less than 65 years old 3 There is at least one target organ dysfunction 4 Previous physical fitness 5 No bad habits (drug use, alcohol addiction)
Who cannot join
- Refuse to join this study
- Missing/incomplete information
- Pregnant women, vulnerable groups such as those who have no capacity for civil conduct and cannot determine the consent of their attorneys
- Chronic organ dysfunction (chronic heart insufficiency, chronic respiratory insufficiency, chronic renal insufficiency, chronic Liver insufficiency)
- Tumors, blood system diseases, various systemic immune diseases
- Various infectious diseases (various hepatitis, tuberculosis, AIDS)
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
SAHZU
Hanzhou, Zhejiang, 310009
Yongan Xu, 13757164833, xuyongan2000@163.com
About this study
Official title: The Correlation Between the Metabolism and the Functional Status of Multiple Organs in the Early Stage of Diquat Poisoning---A Multicenter Observational Study
Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Mistake of Diquat can cause damage to multiple organs throughout the body. It has a high fatality rate and no specific treatment.The treatment method has become a research hotspot of modern poisoning treatment.
The degree of organ dysfunction caused by DQ poisoning is mainly related to the patient's intake and the distribution of the poison in the human body.So far, the distribution concentration of DQ under the influence of the time gradient in the body and the influence of DQ on the human environment，metabolimics,，immune regulation activity and the comprehensive mechanism of action of various inflammatory factors have not been fully elucidated. Therefore, this research mainly focuses on analyzing the internal environment metabolism research in patients with DQ poisoning, and to conduct exploratory research on the severity of the impact on their organ functions
- Conditions
- Diquat Poisoning
- Being tested
- Detect the serum sample
- Keywords
- Diquat Metabolomics Toxicology Multicenter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Detect the serum sampleDiagnostic test
Detect the serum sample
| Study group | Role | What they receive |
|---|---|---|
| patients of Diquat poisoning | Not described Receives: Diagnostic Test: Detect the serum sample | |
| normal persons | Not described Receives: Diagnostic Test: Detect the serum sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
The poison metabolomics of Diquat
Improve the correlation between the concentration and metabolism rate of diquat poisoning in vivo and metabolomics and the co-damage color of body organs for bioinformatics analysis and summary
Measured: 2022-06
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2021
- Study start2 Dec 2021
- Primary completion30 Jun 2022 (estimated)
- Study completion30 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diquat PoisoningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yongan Xu, Study director, SAHZU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05168111
- Sponsor's protocol ID
- 2021-1068
- Status last verified
- Dec 2021
- First submitted
- 15 Dec 2021
- Last updated
- 23 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Correlation Between the Metabolism and the Functional Status of Multiple Organs in the Early Stage of Diquat Poisoning---A Multicenter Observational Study
- ClinicalTrials.gov ID
- NCT05168111
- Acronym / sponsor ID
- 2021-1068
- Conditions
- Diquat Poisoning
- Keywords
- Diquat Metabolomics Toxicology Multicenter
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- 2 Dec 2021 (actual)
- Primary completion
- 30 Jun 2022 (estimated)
- Study completion
- 30 Jun 2022 (estimated)
- First posted
- 23 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Mistake of Diquat can cause damage to multiple organs throughout the body. It has a high fatality rate and no specific treatment.The treatment method has become a research hotspot of modern poisoning treatment.
The degree of organ dysfunction caused by DQ poisoning is mainly related to the patient's intake and the distribution of the poison in the human body.So far, the distribution concentration of DQ under the influence of the time gradient in the body and the influence of DQ on the human environment，metabolimics,，immune regulation activity and the comprehensive mechanism of action of various inflammatory factors have not been fully elucidated. Therefore, this research mainly focuses on analyzing the internal environment metabolism research in patients with DQ poisoning, and to conduct exploratory research on the severity of the impact on their organ functions
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients of Diquat poisoning | – | Diagnostic Test: Detect the serum sample |
| normal persons | – | Diagnostic Test: Detect the serum sample |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute poisoning of diquat are mainly selected.
Key inclusion criteria (1 listed)
- 1.Time from poisoning to hospital admission: within 6 hours, 2 The age is greater than 18 years old, less than 65 years old 3 There is at least one target organ dysfunction 4 Previous physical fitness 5 No bad habits (drug use, alcohol addiction)
Key exclusion criteria (6 listed)
- Refuse to join this study
- Missing/incomplete information
- Pregnant women, vulnerable groups such as those who have no capacity for civil conduct and cannot determine the consent of their attorneys
- Chronic organ dysfunction (chronic heart insufficiency, chronic respiratory insufficiency, chronic renal insufficiency, chronic Liver insufficiency)
- Tumors, blood system diseases, various systemic immune diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Detect the serum sampleDetect the serum sample | Diagnostic test | normal persons, patients of Diquat poisoning |
Primary outcome
The poison metabolomics of Diquat
Time frame: 2022-06
Improve the correlation between the concentration and metabolism rate of diquat poisoning in vivo and metabolomics and the co-damage color of body organs for bioinformatics analysis and summary
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2021.
Related trials for Diquat Poisoning
Active, not recruitingObservational study
Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning
Toxic Encephalopathy, Diquat Poisoning
Not yet recruitingObservational study
Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples
Diquat Poisoning
Not yet recruitingPhase 1
Accelerated HEmodiafiltration in Severe Acute Diquat (AHEAD) Poisoning
Diquat Poisoning
Not yet recruitingPhase 3
Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute Diquat Poisoning
Diquat Poisoning
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yongan Xu study director
SAHZU
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diquat Poisoning, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yongan Xu, Doctor (13757164833, xuyongan2000@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The poison metabolomics of Diquat (time frame: 2022-06). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2021.